

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
25 June 2009 (25.06.2009)

PCT

(10) International Publication Number
WO 2009/076693 A1

(51) International Patent Classification:

C07D 455/02 (2006.01) A61K 31/4375 (2006.01)
C07D 405/06 (2006.01) A61P 3/04 (2006.01)

(21) International Application Number:

PCT/AT2008/000458

(22) International Filing Date:

17 December 2008 (17.12.2008)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

07450235.2 19 December 2007 (19.12.2007) EP
A 1315/2008 25 August 2008 (25.08.2008) AT

(71) Applicant (for all designated States except US):
55PHARMA DRUG DISCOVERY & DEVELOPMENT AG [AT/AT]; Palais Pálffy, Josefsplatz 6, A-1010 Wien (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ADORJAN, Immanuel** [AT/AT]; Judenauerweg 10/2, A-3430 Tulln

(AT). **BAUER, Leonhardt** [AT/AT]; Schottenring 17/11a, A-1010 Wien (AT). **FROBEL, Klaus** [DE/DE]; Paul-Ehrlich-Str. 9, 42113 Wuppertal (DE). **FÜRNISIN, Clemens** [AT/AT]; Hofenedergasse 3/12, A-1020 Wien (AT).

(74) Agents: **SCHWARZ, Albin** et al.; Wipplingerstrasse 30, A-1010 Wien, Autriche (AT).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.






(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

[Continued on next page]

(54) Title: OCTAHYDROQUINOLIZINES FOR ANTIDIABETIC TREATMENT

Figure 1

Table 1 (Fig. 1 to 29)

Table Entry	Name/Formula/Molecular Weight/Structure	Examp. No.	Educt No. (PN)	Product Specification	Product No. (PN)
1	7-methyl-7-phenyloctahydro-2H-quinolizin-2-one C ₁₆ H ₂₁ NO (243.3) 	1		Stereo-isomer A	<u>1</u>
				Stereo-isomer B	<u>2</u>
2	7-methyl-7-phenyloctahydro-2H-quinolizin-2-ol C ₁₆ H ₂₃ NO (245.4) 	2	<u>1</u>	Stereo-isomeric mixture	<u>3</u>
			<u>2</u>	Stereo-isomeric mixture	<u>4</u>
3	2-methoxy-7-methyl-7-phenyloctahydro-2H-quinolizine C ₁₇ H ₂₅ NO (259.4) 	3	<u>3</u>	Stereo-isomeric mixture	<u>5</u>
			<u>4</u>	Stereo-isomeric mixture	<u>6</u>
4	2-(benzyloxy)-7-methyl-7-phenyloctahydro-2H-quinolizine C ₂₃ H ₂₉ NO (335.5) 	4	<u>3</u>	Stereo-isomeric mixture	<u>7</u>
			<u>4</u>	Stereo-isomeric mixture	<u>8</u>
5	2,7-dimethyl-7-phenyloctahydro-2H-quinolizin-2-ol C ₁₇ H ₂₅ NO (259.4) 	5	<u>1</u>	Stereo-isomer a	<u>9</u>
				Stereo-isomer b	<u>10</u>
			<u>2</u>	Stereo-isomer a	<u>11</u>
				Stereo-isomer b	<u>12</u>

(57) Abstract: This invention relates to novel octahydroquinolizines for treatment or prevention of diabetes mellitus and its complications, for treatment or prevention of hyperlipidemia, for treatment of diabetic dyslipidemia, for treatment or prevention of the metabolic syndrome, for treatment of diseases related to metabolic dysfunction, for treatment of obesity or obesity-related diseases. The invention also includes pharmaceutical compositions and kits comprising these compounds alone or in combination with other drugs or compounds aiming towards an improved treatment or prevention of the aforementioned diseases or syndromes in humans or animals.



GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*